Tolerability and Efficacy of Chemotherapy Containing Bedaquiline in Patients with Multiple Drug Resistant Pulmonary Tuberculosis
https://doi.org/10.21292/2075-1230-2022-100-9-40-45
Abstract
The objective: to evaluate safety and efficacy of bedaquiline in the treatment of patients with multiple drug resistant tuberculosis (MDR-TB).
Subjects and Methods. Clinical data of 523 patients above 18 years old registered for MDR TB treatment as per regimen 4 were retrospectively analyzed. HIV-negative patients were selected and divided into two groups by the use of bedaquiline in the chemotherapy regimen.
Results. In MDR TB treatment regimen containing bedaquiline, adverse reactions were observed in 95.7% of cases, the majority of them (65.2%) were of mild or moderate degree of severity. In 30.4% of such cases, bedaquiline was temporarily discontinued (mostly due to hepatotoxic reactions). No cardiotoxicity was observed as a response to bedaquiline, the median corrected QT interval made 413 ms, the maximum value was 438 ms. Adding bedaquiline to the regimen resulted in faster (in the first 3 months of treatment) and more frequent (in 94.7%) sputum conversion by culture (in the regimens with no bedaquiline, it was achieved in 63.8% of cases, p = 0.019). Treatment with regimens containing bedaquiline was effective in 82.61% of patients, while regimens with no bedaquiline were effective in 65.2% of cases, p = 0.085.
About the Authors
O. V. Filinyuk
Siberian State Medical University
Russian Federation
Russian Federation
Olga V. Filinyuk, Doctor of Medical Sciences, Professor, Head of Phthisiology and Pulmonology Department
2, Moskovsky Tr., Tomsk, 634050
D. Yu. Schegertsov
Tomsk Phthisiopulmonology Medical Center
Russian Federation
Russian Federation
Dmitry Yu. Schegertsov, Phthisiologist, Head of MDR Tuberculosis Department no. 2
26, Build. 2, Kuznetsova St., Tomsk, 634050
Phone: +7 (3822) 91-13-55
N. N. Kabanets
Siberian State Medical University
Russian Federation
Russian Federation
Nadezhda N. Kabanets, Senior Teacher of Phthisiology and Pulmonology Department
2, Moskovsky Tr., Tomsk, 634050
D. E. Amichba
Siberian State Medical University
Russian Federation
Russian Federation
Dmitry E. Amichba, Assistant of Phthisiology and Pulmonology Department
2, Moskovsky Tr., Tomsk, 634050
References
1. Borisov S.E., Filippov A.V., Ivanova D.A., Ivanushkina T.N., Litvinova N.V., Garmash Yu.Yu. Efficacy and safety of chemotherapy regimens containing bedaquiline in respiratory tuberculosis patients: immediate and final results. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 5, pp. 28-42. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-5-28-40.
2. Klinicheskie rekomendatsii Tuberkulez u vzroslykh. [Clinical guidelines on tuberculosis in adults]. Approved by the Russian MoH, 2020, 121 p. https://tubercules.org/wp-content/uploads/2020/12/kr-tuberkulez-uvzroslyh-2020.pdf
3. Kondakova M.N., Khabirov V.V., Zhemkov V.F., Shpakovskaya L.R., Daynovets A.V., Elkin A.V. Impact of bedaquiline on the efficacy of comprehensive therapy of respiratory tuberculosis. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 6, pp. 39-43. (In Russ.) doi: 10.21292/2075-1230-2018-96-6-39-43.
4. Konovalova N.M., Odinets V.S., Vasilenko T.I., Zadremaylova T.A. Experience of using bedaquiline in the treatment of pulmonary tuberculosis patients with multiple and extensive drug resistance. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 12, pp. 49-53. (In Russ.) doi: 10.21292/2075-1230-2 017-95-12-49-53.
5. Nechaeva O.B., Son I.M., Gordina A.V., Sterlikov S.A., Kucheryavaya D.A., Dergachev A.V., Ponomarev S.B. Resursy i deyatelnost protivotuberkuleznykh organizatsiy Rossiyskoy Federatsii v 2019-2020 gg. (statisticheskiye materialy). [Resources and activities of TB units in the Russian Federation in 2019-2020. (Statistic materials)]. Moscow, RIO TSNIIOIZ Publ., 2021, 112 p.
6. WHO consolidated guidelines on drug-resistant tuberculosis treatment (2019). World Health Organisation, Regional Office for Europe. (In Russ.) https://apps.who.int/iris/handle/10665/329298. License: CC BY-NC-SA 3.0 IGO.
7. Tikhonova L.Yu., Sokolova V.V., Tarasyuk I.A., Ekimenko A.M., Cherenkova M.A., Kudlay D.A. Experience of treatment of multiple drug resistant tuberculosis patients with bedaquiline in Amur Region. Tuberculosisand Lung Diseases, 2018, vol. 96, no. 6, pp. 45-50. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-6-45-50.
8. Global tuberculosis report 2021. Geneva, World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
9. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. Bethesda, MD, USA: National Institutes of Health, National Cancer Institute, 2010. (Epub.) Available: https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
Review
For citations:
Filinyuk O.V., Schegertsov D.Yu., Kabanets N.N., Amichba D.E. Tolerability and Efficacy of Chemotherapy Containing Bedaquiline in Patients with Multiple Drug Resistant Pulmonary Tuberculosis. Tuberculosis and Lung Diseases. 2022;100(9):40-45. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-9-40-45
Views:
475
Email this article 